A 2-armed randomised phase III study (NCT03983057) is currently comparing the effect of modified-FOLFIRINOX alone in combination with the anti-PD-1 monoclonal antibody nivolumab, in patients with borderline resectable and locally advanced pancreatic cancer. Here, PDCD1 is linked to familial pancreatic carcinoma.